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At the end of cardiac procedures assisted by cardiopulmo-nary bypass (CPB), a large volume of diluted blood(0.75-1.5 L) remains within the extracorporeal circuit.To reduce transfusion requirements, this blood can be
used for autotransfusion with or without processing. One of the
options for processing is the use of a Cell Saver device (Haemonetics,
Braintree, Mass) that concentrates erythrocytes and discards plasma.
During CPB, elevated numbers of cell-derived vesicles, micropar-
ticles, are present that promote coagulation and inflammation. 1 The
aim of this study was to determine the effects of a Cell Saver device
on microparticle counts during a cardiac operation. Heparin and
prothrombin fragment F12 were measured as controls for the effi-
cient removal of low-molecular-weight substances.
Patients and Methods
Patients for elective coronary artery bypass grafting assisted by
CPB (n  13) were included after signed informed consent. This
study was approved by the Medical Ethics Committee of the
Academic Medical Center (Amsterdam, The Netherlands). Blood
was collected before and after processing with a Cell Saver device
(Cell Saver 5). Cell counts were determined on a CellDyn 4000
hematology analyzer (Abbott, Mijdrecht, The Netherlands). Mi-
croparticles, prothrombin fragment F12, and heparin were deter-
mined as described previously.2,3 Concentrations of heparin, mi-
croparticles, and F12 were corrected for hematocrit. Data were
analyzed with SPSS version 11.0 (SPSS, Inc, Chicago, Ill) and
presented as medians (interquartile range). The paired-samples
t test or Wilcoxon signed rank test was used whenever appropriate.
Results and Discussion
All data are summarized in Table 1. Processing with the Cell Saver
device decreased blood volume about 2-fold from 850 mL to 440
mL. As expected, the hematocrit value increased from 0.26 (be-
fore) to 0.55 (after cell salvage; P  .001). The recovery of the
erythrocytes was almost 100% (P  .161). In contrast, about 89%
of the platelets (P  .001) and 31% of the leukocytes (P  .001)
were removed by the Cell Saver device. Small molecules like
heparin and F12 were removed efficiently by 100% (P  .001)
and 98% (P  .003), respectively. The data demonstrating the
efficiency of the Cell Saver device to recover erythrocytes and to
remove platelets, leukocytes, and heparin are all in close agree-
ment with data provided by the manufacturer in the Cell Saver 5
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TABLE 1. Cell Saver device data
Cell Saver device
Removal (%) P valueBefore After
Volume (mL) 850 (796-934) 440 (323-481) 53 (46-63) .001
Hematocrit (L/L) 0.26 (0.24-0.26) 0.55 (48-0.60) NA .001
Erythrocytes (mL) 217 (199-246) 199 (178-253) 3 (5-17) .161
Thrombocytes (109) 140 (85-179) 16 (10-21) 89 (79-91) .001
Leukocytes (109) 4.7 (3.1-6.0) 3.8 (1.5-4.0) 31 (18-45) .001
Heparin (103 IU) 1765 (1666-2053) 9 (4-11) 100 (99-100) .001
F12 (nmol) 2.47 (0.50-7.39) 0.04 (0.03-0.05) 98 (92-99) .003
EryMP (107) 128 (37-292) 5 (2-5) 97 (86-99) .002
PMP (107) 147 (93-191) 1 (1-2) 99 (98-99) .001
Data are presented as medians (interquartile ranges). NA, Not applicable; F12, prothrombin fragment; EryMP, erythrocyte-derived microparticles;
PMP, platelet-derived microparticles.
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erythrocyte recovery; 82% and 24.3% for platelets and leukocytes,
respectively; 97.8% for heparin).
Cell-derived microparticles are, on average, smaller in diameter
than platelets and range in size from about 100 nm to 1.0 m. Thus,
the largest microparticles may overlap in size with platelets, which on
average range in from 1.0 m to 5.0 m. Both erythrocyte-derived
microparticles and platelet-derived microparticles were removed ef-
ficiently (97% and 99%; P  0.002 and P  .001, respectively).
Interestingly, the efficiency of the Cell Saver device to remove
platelet-derived microparticles as well as erythrocyte-derived mi-
croparticles was significantly increased compared with the effi-
ciency to remove thrombocytes (P  .019 and P  .002, respec-
tively; Wilcoxon signed rank test). Thus, cell-derived vesicles,
which on average are smaller in diameter than thrombocytes, are
removed more efficiently from blood by a Cell Saver device than
thrombocytes in a clinical setting.
This study is the first to directly evaluate the efficiency of a Cell
Saver device to remove cell-derived microparticles from patient
blood. Our data show that a Cell Saver device efficiently reduces
the numbers of coagulation- and inflammation-promoting micro-
particles. From these data we cannot exclude that microparticles
may bind to cells present within the blood or that low numbers of
microparticles are generated by cell activation during the passage
of blood through the Cell Saver device.
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Primary intrapulmonary thymoma associated with congenital
hyperhomocysteinemia
Alessando Stefani, MD,a Edouard Boulenger, MD,b Sylvie Mehaut, MD,c Adrian Ciupea, MD,c and Marco Alifano, MD,a
Paris and Troyes, France
Primary intrapulmonary thymomas (PITs) are very un-common, with 28 cases reported to date.1-3 Because ofthe paucity of studies, the biologic behavior and patho-logic features of these neoplasms are not well known.
The C677T methylenetetrahydrofolate reductase (MTHFR) geno-
type is a congenital disorder leading to low folate levels; the
resultant mild hyperhomocysteinemia is associated with increased
risk of venous thromboembolism and malignancies.4,5
We present a case of PIT associated with hyperhomocysteine-
mia caused by the C677T variant of MTHFR.
Clinical Summary
A 73-year-old woman was admitted for acute dyspnea with bron-
chospasm in a chronic obstructive pulmonary disease pathologic
substrate. Her medical history was marked by episodes of venous
thrombosis caused by a mutation of the MTHFR gene that imposed
a preventive anticoagulant therapy. Chest radiography revealed an
18-mm nodule in the right upper lobe, which was confirmed by a
computed tomographic scan (Figure 1). A positron emission to-
mographic scan showed a moderate uptake in correspondence of
the lesion (standardized uptake value, 2.2). The results of bron-
choscopy and computed tomographic scanning of the brain were
normal.
A primary pulmonary tumor was suspected. Thoracotomy was
performed by one of us (E.B.), and a nodule was found in the right
upper lobe close to the hilum. Frozen examination revealed cells of
uncommon feature suspected for malignancy. A right upper lobec-
tomy with full nodal dissection was performed.
Macroscopic examination showed a well-circumscribed and
encapsulated nodule (Figure 2, a ). Histologic evaluation re-
vealed the presence of 2 cell populations: epithelioid and lym-
phocytic (Figure 2, b ). The epithelioid component was predom-
inant and admixed with scattered lymphocytes. No areas of
necrosis and very few mitoses could be identified. Immunohis-
tochemical analysis demonstrated strong staining for cytokera-
tin 5 and 6 and epithelial membrane antigen in the epithelioid
component, with negative staining for cytokeratin 7, thyroid
transcription factor 1, and calretinine. These histologic findings
were consistent with mixed or type AB thymoma. All lymph
nodes were free of tumor.
The postoperative course was uneventful, and the patient is free
of recurrence 2 years after the operation.
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